
Opinion|Videos|July 9, 2024
The Patient Journey: Effectively Managing AD Itch Early On
The panel delves into the most challenging symptoms of atopic dermatitis (AD), maps out the patient journey, and highlights crucial factors in effectively managing itch and other AD-related symptoms.
Advertisement
Episodes in this series

- What are some of the most burdensome symptoms of AD that patients commonly experience, and how do these symptoms impact their quality of life?
- How do you prioritize treating itch in adult patients with atopic dermatitis (AD), and what strategies have you found most effective in managing this symptom promptly?
- Share your experience regarding time to resolution of itch with ruxolitinib topical therapy compared to other treatment options.
- When considering formulary decisions, how is the time-to-disease-control incorporated into these decisions?
Advertisement
Related to this article

Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.

In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.

The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.

CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
3
DME Drug Remigromig Hits Primary End Point in Phase 3 Trial
4
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
5

